Biogen revenue and financials

BIIB · NASDAQ · USD

$223.59+1.69%+$3.71

Close · October 5, 2026

In the fiscal year ended December 2025, Biogen reported revenue of $9.89B (+2.22% year over year). Net income was $1.29B, a net margin of 13.1%.

Annual revenue · 2025: $9.89B

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	9,891	9,676	9,836	10,173	10,982	13,445	14,378	13,453	12,274	11,449
Cost of revenue	2,404	2,310	2,533	2,278	2,110	1,805	1,955	1,816	1,630	1,479
Gross profit	7,808	7,547	7,302	7,895	8,872	11,639	12,423	11,637	10,644	9,970
Selling, general and administrative	2,434	2,387	2,502	2,409	2,680	—	—	—	—	—
Research and development	1,729	1,905	2,442	2,229	2,497	—	—	—	—	—
Operating income	2,848	2,614	1,899	3,019	2,841	4,550	7,043	5,889	5,346	5,152
EBIT	2,848	2,614	1,899	3,019	3,436	—	—	—	—	—
EBITDA	3,628	3,287	2,394	3,537	3,923	—	—	—	—	—
Interest expense	268	250	247	247	254	223	187	201	251	260
Pre-tax income	1,557	1,906	1,297	3,594	1,780	—	—	—	—	—
Income tax	264	274	135	633	52.5	992	1,158	1,426	2,459	1,237
Net income	1,293	1,632	1,161	3,047	1,556	4,001	5,889	4,431	2,539	3,703
Net income to common shareholders	1,293	1,632	1,161	3,047	1,556	—	—	—	—	—
Basic EPS	8.83	11.21	8.02	20.96	10.44	24.86	31.47	21.63	11.94	16.96
Diluted EPS	8.79	11.18	7.97	20.87	10.40	24.80	31.42	21.58	11.92	16.93
Average shares (basic)	147	146	145	145	149	—	—	—	—	—
Average shares (diluted)	147	146	146	146	150	161	187	205	213	219